Olfactory threshold predicts treatment response in relapsing multiple sclerosis

被引:3
|
作者
Bsteh, Gabriel [1 ]
Hegen, Harald [2 ]
Berek, Klaus [2 ]
Altmann, Patrick [1 ]
Auer, Michael [2 ]
Di Pauli, Franziska [2 ]
Haider, Lukas [3 ]
Leutmezer, Fritz [1 ]
Rommer, Paulus [1 ]
Walchhofer, Lisa-Maria [4 ]
Wurth, Sebastian [5 ]
Zinganell, Anne [2 ]
Deisenhammer, Florian [2 ]
Berger, Thomas [1 ]
机构
[1] Med Univ Vienna, Dept Neurol, Waehringer Guertel 18-20, A-1090 Vienna, Austria
[2] Med Univ Innsbruck, Dept Neurol, Innsbruck, Austria
[3] Med Univ Vienna, Dept Neuroradiol, Vienna, Austria
[4] Med Univ Innsbruck, Dept Neuroradiol, Innsbruck, Austria
[5] Med Univ Graz, Dept Neurol, Graz, Austria
关键词
Multiple sclerosis; olfactory threshold; disease-modifying treatment; relapse; MRI; treatment response; INTERFERON-BETA; DYSFUNCTION; SMELL; MRI;
D O I
10.1177/13524585221079744
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Olfactory threshold (OT) is associated with short-term inflammatory activity in relapsing multiple sclerosis (RMS). Objective: We aimed to investigate OT for prediction of treatment response in RMS. Methods: In this 5-year prospective study on 123 RMS patients, OT was measured at disease-modifying treatment (DMT) initiation (M0), after 3 months (M3), and 12 months (M12) by Sniffin' Sticks test. Primary endpoint was defined as an absence of relapse during the observation period, with Expanded Disability Status Scale (EDSS) progression and magnetic resonance imaging (MRI) activity being the secondary endpoints. Optimal cutoff values were determined by receiver operating characteristic analyses and their predictive value assessed by multivariable Cox regression models. Results: Higher OT scores at M0, M3, and M12 were independently associated with decreased relapse probability with the strongest risk reduction at M3 (hazard ratio (HR) = 0.44, p < 0.001). Improvement of OT scores from M0 to M3 (Delta OTM3) was also associated with reduced relapse risk (HR = 0.12, p < 0.001). OT score > 6.5 at M3 was the strongest predictor of relapse freedom (HR = 0.10, p < 0.001) with high diagnostic accuracy (positive predictive value (PPV) = 87%), closely followed by Delta OTM3 > 0.5 (HR = 0.12, p < 0.001, PPV = 86%). Conclusions: OT is an independent predictor of freedom of disease activity upon DMT initiation within 5 years and may be a useful biomarker of treatment response.
引用
收藏
页码:1541 / 1552
页数:12
相关论文
共 50 条
  • [21] OAS1 Genotype Predicts Response to Beta Interferon Therapy in Relapsing Multiple Sclerosis
    Lonergan, Roisin
    O'Brien, Margaret
    Lisa, Costelloe
    Fletcher, Jean
    O'Farrelly, Cliona
    O'Rourke, Killian
    Hutchinson, Michael
    Tubridy, Niall
    NEUROLOGY, 2009, 72 (11) : A489 - A489
  • [22] OAS1 GENOTYPE PREDICTS RESPONSE TO BETA INTERFERON THERAPY IN RELAPSING MULTIPLE SCLEROSIS
    O'Brien, M.
    Lonergan, R.
    Costelloe, L.
    Fletcher, J.
    O'Farrelly, C.
    Rourke, K. O'
    Hutchinson, M.
    Tubridy, N.
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2009, 80 (11):
  • [23] Uric acid as a marker of response to treatment in relapsing-remitting multiple sclerosis
    Azkune Calle, I.
    Sanchez Menoyo, J. L.
    Garcia-Monco, J. C.
    Aguirre Larracoechea, U.
    Ramos, M. Sospedra
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 715 - 715
  • [24] Interferon-β treatment for relapsing multiple sclerosis
    Weinstock-Guttman, Bianca
    Ramanathan, Murali
    Zivadinov, Robert
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2008, 8 (09) : 1435 - 1447
  • [25] Immunomodulatory agents for the treatment of relapsing multiple sclerosis
    Galetta, SL
    Markowitz, C
    Lee, AG
    ARCHIVES OF INTERNAL MEDICINE, 2002, 162 (19) : 2161 - 2169
  • [26] Natalizumab (Tysabri) treatment for relapsing multiple sclerosis
    Johnson, Kenneth P.
    NEUROLOGIST, 2007, 13 (04) : 182 - 187
  • [27] Rational treatment algorithms for relapsing multiple sclerosis
    Herbert, J.
    MULTIPLE SCLEROSIS, 2006, 12 : S81 - S81
  • [28] Evolving concepts in the treatment of relapsing multiple sclerosis
    Comi, Giancarlo
    Radaelli, Marta
    Sorensen, Per Soelberg
    LANCET, 2017, 389 (10076): : 1347 - 1356
  • [29] A recommended treatment algorithm in relapsing multiple sclerosis
    Karussis, D
    Freedman, M
    Fazekas, F
    MULTIPLE SCLEROSIS, 2004, 10 (7032): : S190 - S190
  • [30] Ozanimod for the treatment of relapsing forms of multiple sclerosis
    Kuczynski, Andrea M.
    Oh, Jiwon
    NEURODEGENERATIVE DISEASE MANAGEMENT, 2021, 11 (03) : 207 - 220